These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 28653623)

  • 1. Replication Study: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
    Showalter MR; Hatakeyama J; Cajka T; VanderVorst K; Carraway KL; Fiehn O;
    Elife; 2017 Jun; 6():. PubMed ID: 28653623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Registered report: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
    Fiehn O; Showalter MR; Schaner-Tooley CE; ;
    Elife; 2016 Feb; 5():. PubMed ID: 26943899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
    Ward PS; Patel J; Wise DR; Abdel-Wahab O; Bennett BD; Coller HA; Cross JR; Fantin VR; Hedvat CV; Perl AE; Rabinowitz JD; Carroll M; Su SM; Sharp KA; Levine RL; Thompson CB
    Cancer Cell; 2010 Mar; 17(3):225-34. PubMed ID: 20171147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.
    Gross S; Cairns RA; Minden MD; Driggers EM; Bittinger MA; Jang HG; Sasaki M; Jin S; Schenkein DP; Su SM; Dang L; Fantin VR; Mak TW
    J Exp Med; 2010 Feb; 207(2):339-44. PubMed ID: 20142433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.
    Jin G; Reitman ZJ; Spasojevic I; Batinic-Haberle I; Yang J; Schmidt-Kittler O; Bigner DD; Yan H
    PLoS One; 2011 Feb; 6(2):e16812. PubMed ID: 21326614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutant IDH1 enhances the production of 2-hydroxyglutarate due to its kinetic mechanism.
    Rendina AR; Pietrak B; Smallwood A; Zhao H; Qi H; Quinn C; Adams ND; Concha N; Duraiswami C; Thrall SH; Sweitzer S; Schwartz B
    Biochemistry; 2013 Jul; 52(26):4563-77. PubMed ID: 23731180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations.
    Intlekofer AM; Shih AH; Wang B; Nazir A; Rustenburg AS; Albanese SK; Patel M; Famulare C; Correa FM; Takemoto N; Durani V; Liu H; Taylor J; Farnoud N; Papaemmanuil E; Cross JR; Tallman MS; Arcila ME; Roshal M; Petsko GA; Wu B; Choe S; Konteatis ZD; Biller SA; Chodera JD; Thompson CB; Levine RL; Stein EM
    Nature; 2018 Jul; 559(7712):125-129. PubMed ID: 29950729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.
    Dang L; White DW; Gross S; Bennett BD; Bittinger MA; Driggers EM; Fantin VR; Jang HG; Jin S; Keenan MC; Marks KM; Prins RM; Ward PS; Yen KE; Liau LM; Rabinowitz JD; Cantley LC; Thompson CB; Vander Heiden MG; Su SM
    Nature; 2009 Dec; 462(7274):739-44. PubMed ID: 19935646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enasidenib and ivosidenib in AML.
    Martelli MP; Martino G; Cardinali V; Falini B; Martinelli G; Cerchione C
    Minerva Med; 2020 Oct; 111(5):411-426. PubMed ID: 32955829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reductive carboxylation and 2-hydroxyglutarate formation by wild-type IDH2 in breast carcinoma cells.
    Smolková K; Dvořák A; Zelenka J; Vítek L; Ježek P
    Int J Biochem Cell Biol; 2015 Aug; 65():125-33. PubMed ID: 26007236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of Novel Therapeutics Targeting Isocitrate Dehydrogenase Mutations in Cancer.
    Sharma H
    Curr Top Med Chem; 2018; 18(6):505-524. PubMed ID: 29773061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting isocitrate dehydrogenase (IDH) in cancer.
    Fujii T; Khawaja MR; DiNardo CD; Atkins JT; Janku F
    Discov Med; 2016 May; 21(117):373-80. PubMed ID: 27355333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development.
    Lemonnier F; Cairns RA; Inoue S; Li WY; Dupuy A; Broutin S; Martin N; Fataccioli V; Pelletier R; Wakeham A; Snow BE; de Leval L; Pujals A; Haioun C; Paci A; Tobin ER; Narayanaswamy R; Yen K; Jin S; Gaulard P; Mak TW
    Proc Natl Acad Sci U S A; 2016 Dec; 113(52):15084-15089. PubMed ID: 27956631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IDH mutations in cancer and progress toward development of targeted therapeutics.
    Dang L; Yen K; Attar EC
    Ann Oncol; 2016 Apr; 27(4):599-608. PubMed ID: 27005468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and Characterization of Small-Molecule Inhibitors of the R132H/R132H Mutant Isocitrate Dehydrogenase 1 Homodimer and R132H/Wild-Type Heterodimer.
    Brooks E; Wu X; Hanel A; Nguyen S; Wang J; Zhang JH; Harrison A; Zhang W
    J Biomol Screen; 2014 Sep; 19(8):1193-200. PubMed ID: 24980596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization.
    Ward PS; Lu C; Cross JR; Abdel-Wahab O; Levine RL; Schwartz GK; Thompson CB
    J Biol Chem; 2013 Feb; 288(6):3804-15. PubMed ID: 23264629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Registered report: Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.
    Evans B; Griner E;
    Elife; 2015 Jul; 4():e07420. PubMed ID: 26231040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate.
    Chaturvedi A; Araujo Cruz MM; Jyotsana N; Sharma A; Goparaju R; Schwarzer A; Görlich K; Schottmann R; Struys EA; Jansen EE; Rohde C; Müller-Tidow C; Geffers R; Göhring G; Ganser A; Thol F; Heuser M
    Leukemia; 2016 Aug; 30(8):1708-15. PubMed ID: 27063596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
    Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU
    J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isocitrate dehydrogenase variants in cancer - Cellular consequences and therapeutic opportunities.
    Liu S; Cadoux-Hudson T; Schofield CJ
    Curr Opin Chem Biol; 2020 Aug; 57():122-134. PubMed ID: 32777735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.